News

Latest News

Nasce ON RADAR il laboratorio di pensieri, idee, dialogo

Nasce ON RADAR il laboratorio di pensieri, idee, dialogo

Page available only in Italian language

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, NY, August 19, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline...
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, NY, August 11, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline...
ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.

ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.

ATGC Co., Ltd. (Jang, Sungsu, CEO of ATGC), a biopharmaceutical research and development company, has signed a strategic partnership, license and supply agreement with RELIFE S.r.l...
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology...
Karyopharm and Menarini Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

Karyopharm and Menarini Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

NEWTON, Mass. and FLORENCE, Italy, – July 21, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
Sport’s finest gather under the stars for the grand finale of the XXVI Fair Play Menarini International Award

Sport’s finest gather under the stars for the grand finale of the XXVI Fair Play Menarini International Award

FLORENCE, 8th July 2022 – Intense emotions and immense satisfaction were in the air during the final event of the XXVI Fair Play Menarini International Award. Yesterday evening,...
NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Naarden, the Netherlands, Miami, USA and Florence, Italy; June 28, 2022 – NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of...
The XXVI Fair Play Menarini International Award opens with a press conference at CONI

The XXVI Fair Play Menarini International Award opens with a press conference at CONI

ROME – The opening whistle has blown for the XXVI Fair Play Menarini International Award. This morning, the Salone d’Onore at CONI (the Italian National Olympic Committee) in...
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Florence, Italy and Boston, Mass., June 22, 2022 – The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the...
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Florence, Italy and Boston, Mass., June 6, 2022 - The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the...
Menarini inaugurates new regional headquarters in Dubai, UAE

Menarini inaugurates new regional headquarters in Dubai, UAE

The pharmaceutical group, present in 140 countries in the world, aims to raise standard of patient healthcare across the Middle East and Africa (MEA) region with innovative products and breakthrough research

Dubai, United Arab Emirates, 26 May 2022: Menarini, the leading Italian pharmaceutical group founded in 1886, today opened its regional headquarters in Dubai Science Park as part of its...
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

NEWTON, Mass. and FLORENCE, Italy – May 20th, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

May 20, 2022

Florence, Italy and Boston, Mass., May 20, 2022 - The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the...
Berlin-Chemie Menarini’s position in Ukraine

Berlin-Chemie Menarini’s position in Ukraine

We continue to be deeply concerned by the tragic situation in Ukraine, the devastating losses of civilians and the suffering of the entire Ukrainian population.

1345678910Last

News Archive

 

Company Profile

Download Pdf

youtube Youtube

linkedin Linkedin

Blog Item Image
MENARINI EMPLOYEES
make all the difference, every day.

We are looking for talented people: in order to achieve our mission we need energetic, versatile people with initiative and team-work skills.
Every day we do our jobs with a great sense of commitment, knowing that we are adding more value to the creation of quality drugs.

READ MORE




menarini pills of art

Menarini Pills of Art

Today, with ‘Pills of Art’, Menarini enters the city’s museums to reveal some of the curious facts on the works of the most well-known Renaissance painters. An initiative which confirms the company’s affiliation with art, a close connection which has led them to publish, each year and for more than six decades, an art monograph

Read More
Fair Play Menarini

International Fair Play Menarini Award

International Fair Play Menarini Award: the annual event which celebrates those sporting champions who have stood out in the world of sports for the brilliant results attained whilst fully respecting the rules

Read More
Menarini and Farmindustria

Menarini and Farmindustria: together we won’t rest

COVID -19 has brought many changes to our habits and our daily lives, but together we can face - and overcome - our fears. Menarini and Farmindustria, like all of us, won't rest.

Read More
EFPIA

EFPIA - We won’t rest campaign

MENARINI SUPPORTS THE EFPIA CAMPAIGN - WE WON'T REST: Disease never takes a break, so neither do we. We won't rest until people around the world see a brighter tomorrow.

Read More
newsletter

Subscribe to the newsletter

Subscribe to the newsletter to be updated on Menarini news.

Subscribe
Media Contact

Media Contact

To access the service it is necessary to declare to have read the privacy information.

Read More

The Menarini Blog

MENARINI BLOG

  • Menarini4People
  • WeAreMenarini
I valori Menarini oltre ogni barriera insieme alle Volpi Rosse
Read More
  • News Menarini
Le Volpi Rosse Menarini progettano il futuro e archiviano un 2022 da sogno
Read More
  • Eventi Menarini
  • News Menarini
Tutta l’energia positiva dello sport nella XXVI edizione del Premio Internazionale Fair Play Menarini
Read More

menarini for people

Discover our responsibility projects to stand close to people

read more